Exhibitors & Sponsors

New and updated TLM exhibitor and sponsor information coming available in January.

Be Seen At The Liver Meeting

01

The world’s premier meeting on liver disease provides ample avenues for industry supporters to raise awareness of their products and services. TLM convenes thousands of attendees from around the world to:

  • Learn about the latest advances in hepatology from experts in the field.
  • Explore cutting-edge technology and solutions at our trade show.
  • Renew connections.
  • Build new relationships.          
     

TLM is a unique, lively event that keeps attendees coming back for more each year. It is a unique opportunity to meet and engage your ideal audience – members of the global hepatology community.

7000
Registrants attend The Liver Meeting who have a diverse array of specialty areas. Who will you meet at The Liver Meeting? Become a sponsor or exhibitor and see for yourself.
81
Countries are represented at The Liver Meeting this year! Our attendees travel from around the world to participate in the hottest meeting in hepatology. It is truly a global experience.
AASLD and TLM is a terrific forum for our company to engage with the liver specialist community in a two-way dialogue. Its an action-packed meeting that we prioritize, and we will be back next year!
TLM 2023 Exhibitor
Actions
Satellite Symposia at TLM

 

Friday November 10

12:30 PM - 2:00 PM


Is Primary Biliary Cholangitis on Your Radar?       
Supported by: CymaBay Therapeutics       
Organized by: Medscape Education       
Hynes Convention Center 210


Session Description: Primary biliary cholangitis (PBC) is a chronic, progressive autoimmune disease of the liver, which, if undertreated, can progress to cirrhosis, liver failure, and death. FDA-approved treatment options for PBC are presently limited, and many patients do not have an adequate response to first- and second-line therapies and/or experience adverse effects that limit their use and impair patients’ quality of life. A new generation of PBC therapies with novel mechanisms of action are in late-stage development. In this live, interactive, case-based symposium, expert faculty will review the latest information on the diagnosis and management of PBC and will delve into clinical evidence for emerging therapies. Patient cases will provide clinical context and useful pointers for clinical decision-making in PBC management.


Learning Objectives: Upon completion of this activity, participants will: Have increased knowledge regarding the Impact and burden of PBC on patients’ quality of life, Data on emerging targeted PBC treatments Have greater competence related to Diagnosing PBC in accordance with evidence-based criteria Demonstrate greater confidence in their ability to Implement PBC treatments that address patients’ symptoms.       
Register

 

12:30 PM - 2:00 PM


Innovations in Precision Medicine for Liver Health: Hot Topics From 2023       
Supported by: Perspectum Ltd.       
Organized by: Medscape       
Hynes Convention Center 311


Session Description: Precision medicine that incorporates advanced imaging and genetics, as well as tools like artificial intelligence has the potential to fuel a future of earlier disease detection, diagnosis, and selection of more targeted treatments. Are you aware of the innovations and application of precision medicine tools related to liver disease supported by the latest data? In this 60-minute live symposium, expert faculty will bring you up to date on key topics which include: approaches in precision medicine to assess the liver in health and disease and the latest data in 2023 supporting these approaches. Furthermore, faculty will provide their expert perspectives on the ways precision medicine can be applied in detecting, diagnosing, and treating patients with liver disease. During the Q&A session, you will have an opportunity to ask your questions, so join us in-person at our location in Boston or virtually on our live stream! 


Learning Objectives: Upon completion of this activity, participants will: Have increased knowledge regarding the Clinical utility of precision medicine approaches in liver health and disease. Latest clinical data on precision medicine approaches that integrate imaging technology into liver disease assessment, diagnosis, and treatment. Way that artificial intelligence can support clinical decision-making in liver disease. Have greater competence related to Integrating noninvasive magnetic resonance imaging technology in the management of liver disease. Demonstrate greater confidence in their ability to implement noninvasive tests in the assessment of patients with metabolic dysfunction-associated fatty liver disease/metabolic dysfunction-associated steatohepatitis (MAFLD/MASH) in a team-based environment incorporating perspectives of hepatology and radiology       
Register

 

Saturday November 11


12:30 PM - 2:00 PM


Time to Move the Goalposts? Examining Strategies to Advance HBV Management       
Supported by: GlaxoSmithKline       
Organized by: Clinical Care Options       
Hynes Convention Center 311


Session Description: Join expert faculty as they provide education, perspectives, and recommendations for early HBV treatment and the evolving role of quantitative HBsAg monitoring in people living with chronic hepatitis B.


Learning Objectives: Select appropriate candidates for early HBV treatment after weighing drug- related considerations, cost-benefit considerations, and impact on patient outcomes. Outline the role of quantitative HBsAg in monitoring patients with CHB, including evaluating disease status and predicting disease progression, treatment response, and functional cure. Identify current and future clinical scenarios where quantitative HBsAg monitoring is beneficial to patient management.       
Register

 

12:30 PM - 2:00 PM


Hepatorenal Syndrome: Case-Based Discussion on Evidence-Based Recommendations       
Supported by: Mallinckrodt Pharmaceuticals       
Organized by: Medscape Education       
Hynes Convention Center 210


Session Description: Hepatorenal syndrome (HRS) is a serious functional kidney impairment that occurs as a complication of hepatic cirrhosis. HRS-acute kidney injury (AKI) accounts for 75% of all HRS cases, and is associated with high in-hospital mortality and poor long-term survival without liver transplantation. Despite updated guidelines and therapeutic advancements, the prognosis for high-risk patients remains poor. The early recognition and treatment of HRS-AKI are essential for optimizing both short-term and long-term outcomes. In this interactive MedscapeLIVE! educational symposium, a panel of experts will walk you through a patient case and provide guidance on how to make a prompt diagnosis and effectively manage these patients to improve their outcomes. Join us for this 90- minute CME-certified learning event to get the answers you need for managing your patients with HRS-AKI! 


Learning Objectives: Upon completion of this activity, participants will: Have greater competence related to Identifying the signs of HRS-AKI, Selecting the diagnostic criteria for HRS-AKI, Applying evidence-based treatment options for HRS-AKI, Demonstrate greater confidence in their ability to Integrate new data and guideline recommendations in the management of HRS-AKI       
Register

 

7:30 PM – 9:30PM


Targeting the Metabolic Mechanisms of MASLD and MASH: A Fresh Horizon for Improved Outcomes       
Supported by: Novo Nordisk       
Organized by: Institute for Medical and Nursing Education Inc.       
Boston Marriott Copley Place Salon A-E


Session Description:  Join us for a highly interactive symposium featuring multiple opportunities for audience-expert interaction, including case studies and a question-and-answer session. Learners will hear expert faculty summarize the current understanding of metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH), their relationship with other metabolic disorders, and guideline recommendations for diagnosis and management. There will also be an overview of emerging noninvasive tests for detecting “at-risk” MASH in specialty care. Next, learners will be given the opportunity to put this information to the test in the “What Would You Do?” segment, where they will be challenged to make clinical decisions for people with MASLD/MASH. All symposium learners will have the opportunity to participate in small group virtual practice clinics after the symposium – discussing clinical practice with one of the expert faculty!


Learning Objectives: Explain the metabolic mechanisms that link MASLD/MASH, type 2 diabetes, and obesity, and the role of guideline recommended agents in targeting common disease pathways, Critically review the evidence supporting use of treatments with proven efficacy in MASLD/MASH, including weight management strategies and pharmacotherapies with cardiometabolic benefits, Implement evidence-based guideline and clinical care pathway recommendations for the management of MASLD/MASH, including screening and monitoring, early implementation of appropriate pharmacotherapy, and collaboration with other specialists where relevant.       
Register


Sunday November 12


6:30 AM – 8:30 AM


From Limitations to Long-Term Survival in HCC: Empowering Patients With Early Diagnosis and Novel Immunotherapy-Based Combination Regimens       
Supported by: AstraZeneca       
Organized by: Answers in CME       
Boston Marriott Copley Place (Grand Ballroom Salons F-G)


Session Description: Investigations into novel first-line immunotherapy-based combination regimens for unresectable hepatocellular carcinoma (HCC) have produced new approvals and evidence. In this live in-person event, join Dr. Abou-Alfa and Dr. Singal as they highlight the latest efficacy and safety data for these regimens. Along with a patient advocate, they will discuss practical multidisciplinary strategies for optimizing diagnosis and management so that as clinicians, you can make the most informed treatment decisions possible for patients suffering from this challenging disease.

 

Learning Objectives: Recognize the role of multidisciplinary team in facilitating early diagnosis of hepatocellular carcinoma (HCC), Describe the clinical evidence for immunotherapy-based combination regimens for the first-line treatment of unresectable HCC, Outline evidence-based multidisciplinary strategies to optimize long-term outcomes for patients with unresectable HCC who are treated with first line immunotherapy-based combination regimens.       
Register

 


12:30 PM - 2:00 PM


Exploring New Strategies for the Management of Nonalcoholic Steatohepatitis: NOT a Trivial Pursuit       
Supported by: Madrigal       
Organized by: Medscape Education       
Hynes Convention Center 210


Session Description: The incidence of nonalcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH), continues to rise globally along with an increase in obesity, type 2 diabetes, and other metabolic disorders. Patients at risk of MASH greatly benefit from early identification and intervention. Join us at this interactive, case-based symposium where you can see how your case management strategies compare with those of your peers. Don’t miss out!


Learning Objectives: Upon completion of this activity, participants will: Have increased knowledge regarding the Prevalence and risk factors for NASH, Clinical data for new and emerging treatments for NASH Have greater competence related to Evaluating risk of fibrotic disease and NASH in patients with risk factors Demonstrate greater confidence in their ability to Include new and emerging NASH treatments into treatment strategies.       
Register

Product Theaters at TLM

 

SUNDAY, Nov. 12

10:15 AM – 11:00 AM

 


NASH Explored - Emerging Concepts in Nonalcoholic Steatohepatitis              
Supported by: Madrigal Pharmaceuticals              
Product Theater 1

 


This session will explore several emerging concepts in NASH including: (1) epidemiology and comorbidities, (2) pathophysiology and the role of lipotoxicity in the liver, (3) morbidity and mortality, (4) patient identification and monitoring approaches, and (5) disease management strategies.


10:15 AM – 11:00 AM


Clinical Overview of Rare, Genetic Cholestatic Liver Diseases: PFIC and ALGS              
Supported by: Albireo Pharma, Inc., an Ipsen Company              
Product Theater 2


This presentation will focus on two rare, genetic cholestatic liver diseases: Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC). Drs. Mohammad (Vanderbilt University) and Mavis (Levine Children’s with Atrium Health) will review the clinical presentation, pathophysiology, and diagnosis of ALGS and PFIC and potential approaches for management of pruritus.


12:40 PM – 1:10 PM


Patient-Based Care in Primary Biliary Cholangitis: Reassessing the Management Pathway              
Supported by: Ipsen              
Product Theater 1


In primary biliary cholangitis, it is important to look beyond the liver to make meaningful improvements for patients, so how can we optimize regular disease monitoring alongside the impact of symptoms on patients’ lives? Join us to discuss the remaining unmet patient needs and ways to address them.


12:40 PM – 1:10 PM


Clinical Review: A Treatment for Adults with Acute Hepatic Porphyria, including Acute Intermittent Porphyria              
Supported by: Alnylam Pharmaceuticals              
Product Theater 2


AHP is a rare, genetic disease characterized by debilitating, potentially life-threatening attacks of which the cardinal symptom is severe, diffuse abdominal pain. This presentation will provide a disease overview and review the clinical profile of a treatment for adults with AHP, featuring Phase 3 Study results and open-label extension data.


1:30 PM – 2:00 PM


An Interdisciplinary Approach to Treating Patients with Non-Malignant Ascites              
Supported by: Becton, Dickinson and Company              
Product Theater 1


This symposium will explore the interdisciplinary relationship between Hepatology and Interventional Radiology in treating patients with non-malignant ascites. Dr. Michael Charlton and Dr. George Behrens will discuss their approach and the options they provide for these patients at their Portal Hypertension Clinic at VIR Chicago.


1:30 PM – 2:00 PM


Advancement in the 1L Treatment of Unresectable or Metastatic HCC              
Supported by: Genentech, A Member of the Roche Group              
Product Theater 2


This program will provide an overview of HCC disease and staging, IMbrave150 including the clinical trial design, patient characteristics, pivotal efficacy and safety data, and exploratory subgroup analyses on patients’ risk status, as well as Genentech patient support information.


3:45 PM – 4:30 PM


Innovations in Point-of-care Ultrasound for the Management of MASLD-MASH: Seeing is Believing.              
Supported by: E-Scopics              
Product Theater 1


Come “See” how Hepatoscope two-dimensional ultrasound tools can shift the paradigm of early detection and monitoring of MASLD-MASH. With Hepatoscope, E-Scopics brings LSM and a complete quantification suite of Ultrasound Imaging in the palm of your hand at the point of care; for the assessment of liver steatosis and fibrosis.


3:45 PM – 4:30 PM


Terlipressin and Albumin Use in Hepatorenal Syndrome              
Supported by: Mallinckrodt Pharmaceuticals              
Product Theater 2

 


Monday, November 13

10:15 AM – 11:00 AM


Taking Current PBC Treatment Further              
Supported by: Intercept Pharmaceuticals, Inc.              
Product Theater 1


Join us for an informative presentation that discusses taking treatment for Primary Biliary Cholangitis (PBC) a step further. Learn about an approved therapy for patients with PBC.


10:15 AM – 11:00 AM


Spotlight on MASH (Formerly NASH): Exploring the Pathophysiology and Metabolic Impairments of a Progressive Liver Disease              
Supported by: Novo Nordisk              
Product Theater 2


Join us as we review the pathophysiology of metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH, non-alcoholic steatohepatitis), including the impact of underlying metabolic comorbidities. We will also explore the importance of early diagnosis and intervention for high-risk patients, review current management strategies and highlight the need for future therapies.


12:40 PM – 1:10 PM


Beyond the ALP - The Evolution of Cholestatic Pruritus Management              
Supported by: GSK              
Product Theater 1

Cholestatic pruritus is often considered a significant symptom associated with many liver diseases. This event aims to educate on treating pruritus in parallel to treating the disease, assessing QoL, and scoring and tracking your patient’s itch. Disease experts and a cholestatic patient will lead this compelling event.


12:40 PM – 1:10 PM


Treatment Option for Unresectable Hepatocellular Carcinoma              
Supported by: AstraZeneca              
Product Theater 2


This promotional program covers the HIMALAYA trial of the IMFINZI + IMJUDO immunotherapy regimen in patients with unresectable HCC. The presentation has been updated with results from the HIMALAYA 4-year exploratory analysis showing 1 in 4 patients treated with IMFINZI + IMJUDO was alive at 4 years.


1:30 PM – 2:00 PM


Hepatocellular Carcinoma (HCC) Surveillance Biomarker Landscape Overview              
Supported by: FUJIFILM Healthcare Americas Corporation              
Product Theater 1


HCC surveillance is associated with reduced HCC mortality. However, ultrasound has insufficient sensitivity for early tumor detection, prompting increasing interest in blood-based biomarkers. In this session, we will review the phases of biomarker validation, present the status and data for (protein and liquid biopsy) biomarkers, and discuss ongoing biomarker studies.


1:30 PM – 2:00 PM


NIS4 and NIS2+: Promising Blood-based Biomarkers for NASH Clinical Trials and Patient Care              
Supported by: Labcorp              
Product Theater 2


NIS4® is a blood-based test designed to effectively identify patients with at-risk metabolic dysfunction- associated steatohepatitis (MASH, formerly NASH). The more recently developed NIS2+™ is an optimized version of NIS4® that was designed to improve score robustness. Both can be used for patient management and identification of subjects for MASH clinical trials.


3:45 PM – 4:30 PM


cT1 as a Monitoring Tool in Metabolic Dysfunction-associated Steatotic Liver Disease              
Supported by: Perspectum              
Product Theater 1


In this session we will introduce cT1, a well-established biomarker in liver disease derived from MRI technology. cT1 has played a pivotal role in numerous clinical trials focused on Steatotic Liver Disease, proving its effectiveness in patient selection for enrolment and real-time response monitoring. We will showcase cT1's performance as a marker of response to interventions and explore its practical applications in tailoring individualized patient management strategies.


3:45 PM – 4:30 PM


An Exelixis Product for the Clinical Management of HCC              
Supported by: Exelixis              
Product Theater 2

Contact the AASLD Exhibits & Sponsorship Team

Interested in partnering with AASLD? Contact us for more information.

CONTACT US